Skip to main content

Cancer Survivorship

Cancer survivorship in reconstructive urology and urogynecology is the long-arc care of patients whose cancer treatment has left durable genitourinary, pelvic-floor, sexual, bowel, pain, or psychosocial consequences. This page is a scaffold for future disease-specific expansion - prostate cancer, bladder cancer, testicular cancer, penile cancer, gynecologic cancers, rectal / anal cancers, and pelvic exenteration survivors - while keeping the current focus on the reconstructive problems that change management.

The key organizing principle is simple: survivorship is not "post-treatment maintenance." It is a separate clinical state in which the original cancer, the treatment field, the tissue biology, the patient's sexual and continence goals, and the feasibility of future surveillance all shape reconstructive decision-making.

Planned Expansion Map​

Cancer / treatment groupFuture article depthReconstructive-urology / urogynecology questions
Prostate cancerRadical prostatectomy, radiotherapy, salvage therapy, focal therapyVesicourethral anastomotic stenosis, radiation-induced bulbomembranous stricture, male SUI, ED, penile length loss, rectourethral fistula, devastated outlet
Bladder cancerRadical cystectomy, trimodality therapy, urinary diversion survivorshipDiversion selection, stomal and pouch complications, sexual recovery after cystectomy, urethral recurrence, upper-tract surveillance, diversion-associated secondary malignancy
Testicular cancerOrchiectomy, RPLND, chemotherapy / radiotherapyTesticular prosthesis counseling, fertility preservation, hypogonadism, ejaculatory dysfunction after RPLND, body image
Penile cancerOrgan-sparing surgery, glansectomy, partial / total penectomy, nodal therapyGlans resurfacing / neoglans, penile-sparing reconstruction, perineal urethrostomy, buried penis overlap, sexual and urinary rehabilitation
Gynecologic and pelvic cancersCervical, uterine, vulvar, vaginal, ovarian, rectal / anal, pelvic exenterationVaginal stenosis, SUI / OAB / FI, prolapse, vulvar and vaginal reconstruction, neovagina, flap selection, lymphedema, chronic pelvic pain

Burden of Dysfunction After Pelvic Cancer Treatment​

Pelvic cancer treatments - radical prostatectomy, radical cystectomy, pelvic exenteration, radical hysterectomy, and radiotherapy - produce high rates of late urologic and pelvic-floor morbidity. These complications may persist or worsen over years rather than resolving after the early survivorship window.[1][4][37]

Population / exposureSurvivorship signalReconstructive implication
After prostatectomyAt 12 years, any urinary or sexual complication is 7-fold more likely than in untreated men; incontinence, ED, and urethral stricture are each at least 5-fold increased; AUS placement is 110-fold higher.[1]Screen for SUI, ED, VUAS / BNC, and treatment regret early; counsel that continence and sexual rehabilitation may require staged reconstruction.
After pelvic radiotherapyAt 12 years, urethral stricture is 6-fold higher, radiation cystitis 131-fold higher, radiation proctitis 88-fold higher, and secondary bladder cancer nearly 3-fold higher.[1]Radiation history changes every operation: tissue is hypovascular, graft beds fail more easily, and permanent diversion may be a legitimate endpoint.
Women after pelvic radiotherapyMeta-analysis pooled prevalence: UI 37%, urgency incontinence 47%, OAB 42%, anal incontinence 24%, pelvic pain 30%, sexual dysfunction 19%.[2]Survivorship visits should include bladder, bowel, pain, and sexual-health screening rather than a narrow urinary history.
After gynecologic cancer surgeryUI is common before and after hysterectomy for gynecologic cancer; adjuvant therapy increases odds of moderate-to-severe UI nearly 5-fold.[3]Pelvic-floor symptoms may predate cancer surgery, then worsen after treatment; baseline symptom inventory matters before reconstruction.
ProtecT 12-year prostate-cancer outcomesUrinary leakage persists after prostatectomy, sexual function declines across all arms, and fecal leakage worsens long-term after radiotherapy.[4]Treatment-choice counseling should include late bowel and sexual sequelae, not only oncologic endpoints.

For radiation biology and operative-field implications, see Radiation & Tissue Effects.

Reconstructive Urology Domains​

Urethral stricture, VUAS, and bladder-neck obstruction​

Posterior urethral stenosis occurs in roughly 5-10% of post-prostatectomy patients and 4-13% after radiotherapy, with rates exceeding 40% after salvage prostatectomy.[5] Management should be staged by anatomy, prior radiation, continence status, and patient tolerance for future incontinence treatment.

ScenarioWorking approachCounseling point
First-time vesicourethral anastomotic stenosisDilation or direct vision internal urethrotomy is guideline-supported and succeeds in 50-80% of first-time cases, with lower durability after radiation.[6]Endoscopic success is plausible once; repeated endoscopic cycling should not delay definitive reconstruction.
Radiation-induced bulbomembranous strictureEPA is the classic definitive option, with multi-institutional success around 70-87% at 2-3 years.[7][8][9]Stricture length, patient age, and tissue quality predict recurrence; new or worsened SUI is common enough to discuss before surgery.
Post-prostatectomy / post-radiation anastomotic stenosisDorsal onlay BMG urethroplasty is an emerging continence-preserving option in selected patients.[10]BMG may reduce de novo incontinence risk compared with excisional approaches, but patient selection is critical.
Complex radiation outlet / devastated bladder outletRobotic reconstruction is emerging; free ileal flap reconstruction and urinary diversion are salvage options for select catastrophic outlets.[6][11][14]The decision is often reconstruction versus planned permanent diversion, not "one more endoscopic attempt."

Patients undergoing urethroplasty for radiation-induced stenosis should be counseled that stress urinary incontinence may develop in 19-40%, and roughly 22% may later require AUS placement.[12][13][8] See Urethral Reconstruction, Bladder Neck Reconstruction, and Incontinence.

Devastated bladder outlet and diversion​

When the outlet is densely fibrotic, necrotic, fistulized, intolerably painful, or paired with refractory incontinence, urinary diversion with or without cystectomy may be the most restorative operation rather than a failure of reconstruction.[14] In a prospective cohort of 55 patients undergoing diversion for pelvic radiation injury, PROMIS Global Health, genitourinary pain, and quality of life improved with low decision regret.[15]

The survivorship version of diversion counseling should include:

  • Whether the bladder should be left in situ or removed.
  • Whether the patient can manage a stoma, catheterizable channel, or neobladder.
  • Prior bowel resection, pelvic radiation dose, renal function, B12 risk, metabolic acidosis risk, mucus burden, and future surveillance feasibility.
  • The possibility that pain relief and infection control may be the primary goals, even when continence cannot be restored.

See Urinary Diversion, Mucus Management, Vitamin B12 Supplementation, and Urinary Acidifiers & Alkalinizers.

Radiation / hemorrhagic cystitis​

Radiation cystitis affects 5-15% of patients after pelvic radiotherapy and can present months to decades after treatment.[16] Management is stepwise:

  1. Stabilize bleeding: catheter drainage, clot evacuation, continuous bladder irrigation, correction of coagulopathy, and cystoscopic fulguration when needed.
  2. Treat irritative symptoms and infection-like presentations without assuming bacteriuria explains the whole syndrome.
  3. Offer hyperbaric oxygen therapy for persistent radiation cystitis: RICH-ART showed significant symptom and quality-of-life improvement, and long-term follow-up showed durable benefit with lower health-care cost.[16][18]
  4. Consider intravesical glycosaminoglycan replacement or other intravesical hemostatic / regenerative options in selected patients.[19][20]
  5. Reserve salvage cystectomy and diversion for refractory, life-altering bleeding, pain, contracted bladder, fistula, or repeated hospitalization.[22]

A 2024 meta-analysis found HBOT safe and effective for radiation-induced hemorrhagic cystitis, with complete hematuria remission in a substantial subset.[17] Emerging agents such as oral chlorophyllin are investigational and should be framed as early-phase evidence.[21]

Secondary malignancy after reconstruction​

Secondary malignancies arising within urologic reconstructions are rare but high-consequence. In a multi-institutional case series, tumors appeared at a median of 36 years after reconstruction, were predominantly adenocarcinoma, often presented at advanced stage, and were aggressive.[23] This belongs in every survivorship plan for patients with bowel incorporated into the urinary tract: the surveillance horizon is measured in decades.

Urogynecologic Reconstruction and Pelvic-Floor Survivorship​

NCCN disease-specific survivorship guidance for uterine, cervical, vulvar, and vaginal cancer emphasizes that surgery and radiotherapy may cause adhesions, urinary and bowel complications, pelvic-floor dysfunction, lymphedema, sexual dysfunction, and chronic pain.[24][25][26][27]

Pelvic-floor survivorship should separate three overlapping problems:

ProblemMore linked to surgeryMore linked to radiotherapyReconstructive frame
Stress urinary incontinence / prolapseRadical pelvic surgery, hysterectomy, denervation, fascial disruptionMay coexist but is not purely radiation-drivenConsider pelvic floor PT first; sling, bulking, Burch, AUS, or prolapse repair only after oncologic anatomy and tissue quality are understood.
Urgency, OAB, bladder pain, vaginal stenosisBladder denervation and perioperative injuryRadiation cystitis, fibrosis, stenosis, mucosal fragilityTreat GSM / atrophy, pain, and bladder hypersensitivity before labeling surgery a failure.
Fecal / anal incontinence and dyspareuniaExenteration, rectal surgery, radical hysterectomyRectal dose, proctitis, fibrosisMultidisciplinary pelvic-floor care is usually required; continence, sexual function, and pain cannot be managed in separate silos.

Combined gynecologic oncology and urogynecology surgery is feasible in selected patients. In a 102-patient series of concurrent gynecologic oncology and urogynecology procedures, the complication rate was 9.8% without major morbidity events.[28] A systematic review of pelvic-floor dysfunction after gynecologic cancer surgery and adjuvant therapy highlights conservative management - pelvic floor muscle training, biofeedback, vaginal dilators, and lifestyle modification - before surgical escalation.[29]

See Prolapse Repair, Incontinence, Pelvic Floor Physical Therapy, GSM, and Female Sexual Dysfunction.

Perineal and Vaginal Reconstruction After Exenteration​

Pelvic exenteration with reconstruction is sometimes the only curative option for advanced or recurrent pelvic malignancy. Neovaginal and perineal reconstruction should be planned around dead-space obliteration, durable pelvic-floor closure, sexual goals, radiation history, stoma / diversion placement, and donor-site morbidity.

A multicenter review of gynecologic reconstruction in the context of pelvic exenteration found neovaginal reconstruction safe in selected patients, with 66% experiencing no long-term morbidity, neovaginal stenosis in 7%, and procedure-specific major morbidity of 5.2%.[30] Flap options include VRAM, gracilis, IGAP, lotus petal, and other regional or free-tissue strategies.[31][32] Long-term outcomes can include high global quality of life despite severely impaired sexual function, making sexual rehabilitation and expectation-setting central rather than optional.[32]

See Genital Reconstruction, Fistula Repair, and Tissue Transfer.

Sexual Health and Rehabilitation​

Sexual dysfunction is one of the most common and least reliably addressed survivorship problems. NCCN Survivorship recommends regular screening using validated tools such as FSFI, SHIM, and PROMIS SexFS, with proactive clinician initiation rather than waiting for the patient to volunteer concerns.[33] ASCO similarly recommends that a member of the care team initiate discussion at diagnosis and reassess throughout follow-up.[36]

Patient groupCommon issuesInitial rehabilitation frame
Cisgender male survivorsED after prostatectomy / cystectomy / radiotherapy, climacturia, penile shortening, low testosterone, Peyronie's overlap, orgasmic changePDE5 inhibitors, VED / traction where appropriate, ICI / MUSE, penile prosthesis for refractory ED, testosterone evaluation when clinically appropriate
Cisgender female survivorsDyspareunia, dryness, vaginal stenosis, arousal / orgasm change, body-image distress, pain with penetration, sexual avoidanceLubricants / moisturizers, topical lidocaine, low-dose vaginal estrogen or DHEA when oncologically appropriate, dilators, pelvic floor PT, psychosexual counseling
Diversion / exenteration survivorsAltered body image, stoma-related intimacy barriers, neovaginal stenosis, loss of ejaculation or vaginal depth, relationship distressExplicit counseling on self-pleasure, non-penetrative intimacy, pouch / appliance management, partner communication, referral to sexual-medicine specialists

After radical cystectomy, qualitative data show that many women receive little or no information about sexual dysfunction and want more complete counseling, including self-pleasure and non-intercourse intimacy.[34] Post-cystectomy patients of all sexes may experience significant sexual distress that requires individualized rehabilitation rather than a one-size device or medication algorithm.[35]

See Male Sexual Dysfunction, Penile Implants, and Female Sexual Dysfunction.

Chronic Pelvic Pain​

Cancer survivors with chronic GI, urinary, or pelvic pain should be evaluated for recurrent cancer and treatable complications, but persistent pain also deserves a rehabilitation pathway. NCCN Survivorship frames pelvic pain care as multidisciplinary: urology, gynecology, physical medicine and rehabilitation, pelvic-floor physical therapy, bowel regimen, hydration, psychosocial care, and selected neuromodulation for chronic cystitis-type pain.[33]

In reconstructive practice, chronic pelvic pain should trigger a structured review:

  • Is there radiation cystitis, contracted bladder, fistula, infection, stone, obstruction, retained bladder syndrome, or pubic symphysis osteomyelitis?
  • Is there pelvic-floor overactivity, levator spasm, neuropathic pain, vaginal stenosis, or dyspareunia?
  • Is the goal restoration of anatomy, pain control, continence, sexual function, or the ability to stop repeated emergency visits?
  • Would another reconstructive attempt help, or would diversion / extirpation better match the patient's goals?

Survivorship Care Model​

The NCCN Survivorship framework defines six standards that apply directly to reconstructive urology and urogynecology survivors: recurrence surveillance and subsequent-cancer screening; monitoring long-term physical, psychosocial, cognitive, and immunologic effects; prevention and detection of late effects; management of cancer-related syndromes with referral; coordination between primary care and specialists; and planning for ongoing care including physical activity, nutrition, alcohol avoidance, smoking cessation, and weight management.[33]

For this page, the practical clinic template is:

Visit domainMinimum survivorship screenWhy it matters reconstructively
Cancer status and field historyCancer type, stage, surgery, radiation dose / field, chemotherapy, immunotherapy, recurrence statusDetermines tissue biology, operative risk, and whether symptoms might represent recurrence.
Urinary functionPads, catheterization, retention, UTIs, hematuria, urgency, pain, renal function, upper-tract imagingIdentifies outlet obstruction, radiation cystitis, diversion complications, and reconstruction failure.
Bowel and pelvic-floor functionFI, constipation, radiation proctitis, pelvic-floor spasm, prolapse symptomsUrinary reconstruction often fails if bowel dysfunction and pelvic-floor pain are ignored.
Sexual health and body imageDesire, arousal, erections, lubrication, dyspareunia, orgasm, intimacy goals, distressSexual rehabilitation should be offered before and after reconstruction, not only after the patient asks.
Psychosocial and decision qualityRegret, anxiety, depression, partner concerns, work / activity limitations, ostomy distressComplex reconstruction is preference-sensitive; regret and distress change the operative endpoint.
Long-term surveillanceSubsequent primary cancers, reconstructed urinary tract surveillance, stoma / pouch / augmented bladder reviewSecondary cancers and bowel-segment complications may appear decades later.[23]

Key Takeaways​

  • Pelvic cancer treatment creates durable urologic, pelvic-floor, bowel, sexual, and pain syndromes; these do not reliably fade after the first few years.[37][4]
  • Prior radiation changes the reconstructive equation: success rates, incontinence risk, graft reliability, fistula risk, and the threshold for urinary diversion all shift.
  • Reconstructive procedures can improve quality of life, but they need survivorship-specific counseling about morbidity, staged care, sexual function, and lifelong surveillance.
  • Sexual health screening should be routine and proactive for all survivors.
  • The best care model is multidisciplinary: reconstructive urology, urogynecology, oncology, pelvic-floor PT, sexual medicine, psychology, pain medicine, ostomy care, and primary care.

Cross-references​

References​

1. Unger JM, Till C, Tangen CM, et al. Long-term adverse effects and complications after prostate cancer treatment. JAMA Oncol. 2024. doi:10.1001/jamaoncol.2024.4397

2. Perez CDA, Rocha AKL, Volpato MP, et al. Prevalence of pelvic floor dysfunction in women after pelvic radiotherapy: systematic review and meta-analysis. Int Urogynecol J. 2026. doi:10.1007/s00192-026-06557-z

3. Brennen R, Lin KY, Denehy L, et al. Natural history of pelvic floor disorders before and after hysterectomy for gynaecological cancer. BJOG. 2024;131(11):1545-1554. doi:10.1111/1471-0528.17870

4. Donovan JL, Hamdy FC, Lane JA, et al. Patient-reported outcomes 12 years after localized prostate cancer treatment. NEJM Evid. 2023;2(4):EVIDoa2300018. doi:10.1056/EVIDoa2300018

5. Herschorn S, Elliott S, Coburn M, Wessells H, Zinman L. SIU/ICUD consultation on urethral strictures: posterior urethral stenosis after treatment of prostate cancer. Urology. 2014;83(3 Suppl):S59-S70. doi:10.1016/j.urology.2013.08.036

6. Wessells H, Morey A, Souter L, Rahimi L, Vanni A. Urethral stricture disease guideline amendment (2023). J Urol. 2023;210(1):64-71. doi:10.1097/JU.0000000000003482

7. Hofer MD, Zhao LC, Morey AF, et al. Outcomes after urethroplasty for radiotherapy induced bulbomembranous urethral stricture disease. J Urol. 2014;191(5):1307-1312. doi:10.1016/j.juro.2013.10.147

8. Voelzke BB, Leddy LS, Myers JB, et al. Multi-institutional outcomes and associations after excision and primary anastomosis for radiotherapy-associated bulbomembranous urethral stenoses following prostate cancer treatment. Urology. 2021;152:117-122. doi:10.1016/j.urology.2020.11.077

9. Fuchs JS, Hofer MD, Sheth KR, et al. Improving outcomes of bulbomembranous urethroplasty for radiation-induced urethral strictures in post-Urolume era. Urology. 2017;99:240-245. doi:10.1016/j.urology.2016.07.031

10. Sterling J, Simhan J, Flynn BJ, et al. Multi-institutional outcomes of dorsal onlay buccal mucosal graft urethroplasty in patients with postprostatectomy, postradiation anastomotic stenosis. J Urol. 2024;211(4):596-604. doi:10.1097/JU.0000000000003848

11. Sorensen TJ, Elbakry AA, Ratanapornsompong W, et al. Posterior urethral reconstruction with ileal chimeric free flap: a novel approach for management of radiation-induced devastated bladder outlet. Urology. 2025. doi:10.1016/j.urology.2025.10.014

12. Sapienza LG, Ning MS, Carvalho EF, et al. Efficacy and incontinence rates after urethroplasty for radiation-induced urethral stenosis: a systematic review and meta-analysis. Urology. 2021;152:109-116. doi:10.1016/j.urology.2021.02.014

13. Meeks JJ, Brandes SB, Morey AF, et al. Urethroplasty for radiotherapy induced bulbomembranous strictures: a multi-institutional experience. J Urol. 2011;185(5):1761-1765. doi:10.1016/j.juro.2010.12.038

14. Martins FE, Holm HV, Lumen N. Devastated bladder outlet in pelvic cancer survivors: issues on surgical reconstruction and quality of life. J Clin Med. 2021;10(21):4920. doi:10.3390/jcm10214920

15. Woodle T, Kurtzman JT, Ramsay J, McCormick B, Myers JB. A prospective analysis of patient-reported health-related quality of life outcomes following urinary diversion for pelvic radiation-related injury. Urology. 2026. doi:10.1016/j.urology.2026.01.017

16. Oscarsson N, Muller B, Rosen A, et al. Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): a randomised, controlled, phase 2-3 trial. Lancet Oncol. 2019;20(11):1602-1614. doi:10.1016/S1470-2045(19)30494-2

17. Yang TK, Wang YJ, Li HJ, et al. Efficacy and safety of hyperbaric oxygen therapy for radiation-induced hemorrhagic cystitis: a systematic review and meta-analysis. J Clin Med. 2024;13(16):4724. doi:10.3390/jcm13164724

18. Oscarsson N, Rosen A, Muller B, et al. Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): long-term follow-up of a randomised controlled, phase 2-3 trial. EClinicalMedicine. 2025;83:103214. doi:10.1016/j.eclinm.2025.103214

19. Sanguedolce F, Meneghetti I, Bevilacqua G, et al. Intravesical instillation with glycosaminoglycan replacement treatment in patients suffering radiation-induced haemorrhagic cystitis: when and which patients can benefit most from it? Urol Oncol. 2022;40(7):344.e19-344.e25. doi:10.1016/j.urolonc.2022.02.013

20. Kam J, Abu-Ghanem Y, Del Guidice F, et al. Cystoscopic application of RADA16 peptide for refractory haematuria from radiation cystitis. BJU Int. 2025. doi:10.1111/bju.70075

21. Prakash G, Sharma D, Chopra S, et al. A phase II study of oral chlorophyllin in haemorrhagic cystitis secondary to radiation therapy for pelvic malignancies (CLARITY). J Clin Oncol. 2024;42(Suppl 23):48. doi:10.1200/JCO.2024.42.23_suppl.48

22. Pascoe C, Duncan C, Lamb BW, et al. Current management of radiation cystitis: a review and practical guide to clinical management. BJU Int. 2019;123(4):585-594. doi:10.1111/bju.14516

23. Cornell C, Khani F, Osunkoya AO, et al. Secondary malignancy after urologic reconstruction procedures: a multi-institutional case series. Hum Pathol. 2022;119:69-78. doi:10.1016/j.humpath.2021.11.004

24. National Comprehensive Cancer Network. Uterine Neoplasms. Updated 2025-11-14. https://www.nccn.org

25. National Comprehensive Cancer Network. Cervical Cancer. Updated 2025-11-10. https://www.nccn.org

26. National Comprehensive Cancer Network. Vulvar Cancer. Updated 2026-01-06. https://www.nccn.org

27. National Comprehensive Cancer Network. Vaginal Cancer. Updated 2025-12-04. https://www.nccn.org

28. Kohut A, Whitaker T, Walter L, et al. Feasibility of combining pelvic reconstruction with gynecologic oncology-related surgery. Int Urogynecol J. 2023;34(1):177-183. doi:10.1007/s00192-022-05212-7

29. Kurtulus D, Arkan K, Suceken FY, et al. Pelvic floor dysfunction following gynecologic cancer surgery and adjuvant therapy: epidemiology, mechanisms, and management - a systematic review. Int Urogynecol J. 2026. doi:10.1007/s00192-026-06522-w

30. A review of functional and surgical outcomes of gynaecological reconstruction in the context of pelvic exenteration. Surg Oncol. 2024;52:101996. doi:10.1016/j.suronc.2023.101996

31. Bini A, Stavrianos S. Pelvic and perineal reconstruction after bowel, gynecological or sacral tumor resection: a case series. J Clin Med. 2025;14(9):3172. doi:10.3390/jcm14093172

32. Assi H, Persson A, Palmquist I, et al. Sexual and functional long-term outcomes following advanced pelvic cancer and reconstruction using vertical rectus abdominis myocutaneous and gluteal myocutaneous flap. Eur J Surg Oncol. 2021;47(4):858-865. doi:10.1016/j.ejso.2020.09.025

33. National Comprehensive Cancer Network. Survivorship. Updated 2026-04-08. https://www.nccn.org

34. Ceasar RC, Ladi-Seyedian SS, Escobar D, et al. "I think my vagina is still there?": women's perspectives on sexual function and dysfunction following radical cystectomy for bladder cancer, a qualitative study. J Sex Med. 2024;21(5):464-470. doi:10.1093/jsxmed/qdae025

35. Zhang M, Zhou Y. Sexual distress in patients after radical cystectomy for bladder cancer: a qualitative study. Support Care Cancer. 2026;34(2):151. doi:10.1007/s00520-026-10380-z

36. Carter J, Lacchetti C, Andersen BL, et al. Interventions to address sexual problems in people with cancer: American Society of Clinical Oncology clinical practice guideline adaptation of Cancer Care Ontario guideline. J Clin Oncol. 2018;36(5):492-511. doi:10.1200/JCO.2017.75.8995

37. Adams E, Boulton MG, Horne A, et al. The effects of pelvic radiotherapy on cancer survivors: symptom profile, psychological morbidity and quality of life. Clin Oncol (R Coll Radiol). 2014;26(1):10-17. doi:10.1016/j.clon.2013.08.003